About Us
About Edge Our Culture Core Competence Reward and Qualification History
Products
Multi-Port Endoscopic Surgical Robotic System Single-Port Endoscopic Surgical Robotic System Tele-Surgery System Bronchoscopy Robotic System
Empowerment Center
Academic Research
News Center
Corporate News
Contact Us
Contacts Feedback download
EN
中文 En 繁体
About Us
Minimally invasive surgery innovative solution provider
Home
About Us
About Edge
About Edge Our Culture Core Competence Reward and Qualification History
About Edge
Headquartered in Shenzhen, China, Edge Medical is a global leader in surgical robotics innovation. Backed by renowned investors such as Sequoia Capital, Temasek Holdings, and Obimed, we are driven by the mission to "Advancing Surgery, Elevating Care," delivering high-quality robotic solutions to healthcare institutions worldwide.
Edge Medical® has a interdisciplinary R&D and manufacturing team of nearly 1,000 members. With over a decade of technological accumulation and refinement, our core surgical robotic systems are world-leading. Our company has established a robust and complete product portfolio, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and bronchoscopic surgical robots.
Edge Medical® is the world’s second company to master multi-port, single-port, and bronchoscopic robotic technologies. In 2024, we conducted a groundbreaking transcontinental tele-surgery spanning from Rome and Bordeaux in Europe to Beijing, China, setting a new milestone in the history of human surgery.
With employees and partners spanning over 60 countries, Edge Medical aims to advance surgical practices through technological innovation, accelerate the global adoption of robotic surgery, and improve patient outcomes worldwide.
Edge Medical is China’s first and the world’s second company to offer multi-port, single-port, and bronchoscopic surgical robots

Extraordinary R&D Capabilities — Established a comprehensive proprietary intellectual property system with core technology modules in surgical robot. Over 800 patents grants and applications globally.


Support from leading investors worldwide  —  With RMB360 million registered capital, Edge Medical has successfully attracted investors with the deepest understanding of medical technology, including Boyu, Temasek, Sequoia, 3H Health, LYFE Capital, China State-Owned Enterprise Mixed Ownership Reform Fund and OrbiMed since established. Edge Medical was valued at over US$1.5 billion by the crossover round in December 2021.

Extraordinary R&D Capabilities  —  
As of May 4, 2025
8000+
Surgeries completed by Edge® Multi-Port Surgical Robot
1000+
Surgeries completed by Edge® Single-Port Surgical Robot
300+
Surgeries completed by Edge Cloud® Remote Surgery System
Our Culture
Mission
To advance surgical technology, empower surgeons and benefit patients
Vision
To equip every surgical room with surgical robot
Faith
To persistently pursuit of perfection in technologies to create the finest products
Core Competence
Our core team is comprised of scientists from the most prestigious domestic and international educational institutions including Massachusetts Institute of Technology, Harvard University, London Business School, and Peking University and experienced engineers from leading technology companies such as Siemens and Huawei. They specialize in a wide range of disciplines, including mechanical engineering, medicine, medical engineering, computer graphics, computer science, electronic engineering, hylology and artificial intelligence.
We established a comprehensive proprietary intellectual property system with core technologies in structural design, system control, motion planning and AI algorithms in 8 years.
＞
800
Over 800+ patents grants and applications globally
Reward and Qualification
2019
The company was rated as
the Top 50 of Technological and Innovative Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area
2020
The company was rated as
the Top 50 of Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area
2021
The company was rated as
the Top 100 of Fast-growing Enterprises in Shenzhen (ranked top 5)
2022
The company was rated as
Member of Shenzhen Robotics Association
2022
The company was rated as
Member of Shenzhen Medical Device Quality Promotion Association
2023
The company was rated as
Guangdong Surgical Robotics Engineering Research Center
Our History
To capitalize the vast market opportunities and address the unmet clinical needs in China, Edge Medical was dedicated to designing, developing, and manufacturing of surgical robots since its inception in 2017. we completed the design and major R&D of both Edge MP1000 and Edge SP1000 in only four years with both products being eligible for expedited review through the Green Path channel of the NMPA for innovative medical devices. In December 2022, we received the registration approval from the NMPA for MP1000.
2017~2019
Begin
2020~2021
Leap
2022~2023
Breakthrough
2024-2025
Lead
2017~2019
Early stage of operation with the ambition to lead the transformation of the high-end medical devices market in China
2017
05
Edge Medical was founded
2018
01
completed series Angel financing
2018
10
completed series A financing
2018
12
developed the prototype of MP1000 and completed the first animal testing
2019
10
developed the typeset products of both MP1000 and SP1000, and commenced pilot scale production
2020~2021
Strides in a competitive environment to lead the industry
2020
04
completed series A+ financing
2020
09
completed Pre-B financing
2021
02
completed series B financing with over RMB 500 million
2021
10
initiated the registrational clinical trial of SP1000 in gynecologic surgery (the first in China initiated pivotal clinical trial in gynecology for single-port endoscopic surgical robot)
2021
12
completed registrational clinical trial of MP1000 in urologic surgery
completed series crossover financing with over USD 200 million, post-money valuation is over USD 1.5 billion
partnership with Chinese Urological Association and Class III Grade A hospitals to build a national network of training centers
2022~2023
Continued pursuit of perfection and breakthrough to create the finest products
2022
04
Developed CP1000 prototype and completed the animal testing
2022
07
Completed patient enrollment for the registrational clinical trial of SP1000 in gynecologic surgery
2023
08
MP1000 received NMPA approval for all laparoscopic surgeries. Launched MP1000 Plus.
2023
11
SP1000 received NMPA approval for all laparoscopic surgeries
2024-2025
High quality development, continuously leading the innovation of surgical robot solutions
2024
06
Won the National Science and Technology Progress Award for 2023
2024
08
Launched MP2000
2024
09
Launched Edge Cloud telesurgery system. Launched “Thousand-hospital Medical Alliance Membership Program”. Launched SP1000 Plus. Released “3-in-1”solution
2024
02
CP1000 received NMPA approval